TORSKAL

TORSKAL

Biotechnology Research

🌿 Green nanoparticles for cancer therapy

About us

TORSKAL is an international biotech/medtech company, a pioneer of green nanotechnology. We design disruptive gold nanoparticles for cancer therapy from green chemistry. We are committed to the development of a new generation of non-toxic and eco-friendly nanomaterials for the treatment of surface and deep cancers by green chemistry. We have discovered an innovative, green, and patented way of producing gold nanoparticles, leveraging Indian Ocean endemic plants, that have many applications in health. Our first and main project, the Nanotheranostics Project (NT1), a treatment for skin cancer using near-infrared (IR) radiation-induced plasmonic phototherapy is entering phase 1 of clinical trials by the end of 2021. This will be followed by our second project, Deep Cancer (NT2), which aims to develop new nanotheranostics for the treatment of deep cancers such as prostate and pancreatic cancers is currently in the drug phase. We also sell our unique gold nanoparticles through our website's e-commerce platform which has a wide range of applications in diagnostics, research, industry, and others. TORSKAL is currently located in Europe (France, La Réunion), China, and the US.

Website
https://www.torskal.com
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Sainte-Clotilde
Type
Privately Held
Founded
2015
Specialties
Nanotechnology, Nanomedicine, Biotechnology, Nanotheranostics, Nanoparticles, Gold Nanoparticles, Cancer Research, and Green Nanotechnology

Locations

Updates

Similar pages

Funding

TORSKAL 1 total round

Last Round

Undisclosed

US$ 2.2M

See more info on crunchbase